Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Cardiology-CTVS
  • Cardiology & CTVS News
  • MRA Strongly...

MRA Strongly Recommended in Treatment of Heart Failure with Reduced Ejection Fraction: 2021 ESC Guidelines

Written By : Medical Dialogues Bureau |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2021-11-17T12:45:40+05:30  |  Updated On 9 Oct 2023 12:39 PM IST
MRA Strongly Recommended in Treatment of Heart Failure with Reduced Ejection Fraction: 2021 ESC Guidelines
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

Pharmacotherapy is the cornerstone of treatment for Heart Failure with Reduced Ejection Fraction (HFrEF) and should be implemented before considering device therapy, and alongside non-pharmacological interventions.

The recently issued guidelines strongly recommend the use of mineralocorticoid Receptor Antagonist (MRA) in addition to an ACE-I and a beta-blocker, in all patients with HFrEF to reduce mortality and the risk of HF hospitalization (class 1A recommendation).

This marks a major change from the previous European Society of Cardiology (ESC) guidelines on the same topic issued in 2016, where only ACE-I and beta-blockers were class IA recommendations. In contrast, the recent guidelines mark the strong change in approach calling for the initiation of MRAs (Spironolactone or Eplenorone) along ACE-I and beta-blockers quickly and safely as possible.

Heart failure (HF) is a global pandemic affecting at least 26 million people worldwide1with an increasing prevalence of heart failure in India due to coronary heart disease, hypertension, obesity, diabetes, and rheumatic heart disease ranging from 1.3 to 4.6 million, with an annual incidence of 491 600–1.8 million.2

People with heart failure develop a poor quality of life due to various symptoms such as shortness of breath, dysphagiafatigue, sleeping difficulties, etc which takes their mental well being consequently affecting the quality of life. Poor QOL is related to high hospitalization and mortality rates.3-6

At regular intervals, the ESC releases guidelines to help health professionals manage people with heart failure (HF) according to the best available evidence. This year ESC has revised the format of the previous 2016 ESC HF Guidelines to make each phenotype of HF stand-alone in terms of its diagnosis and management.

On the issue of MRA, the guidelines strongly recommend the use of MRAs in all patients with heart failure with left ventricular reduced ejection fraction (LVEF<40%) to reduce mortality and the risk of HF hospitalization (class1A recommendation). In cases of Heart Failure with Mild Reduced Ejection Fraction (HFmrEF), the guidelines recommend that MRA may be used (a classII b level C) to reduce the risk of HF, hospitalization, and death.

Aldosterone receptor antagonists (also called anti mineralocorticoid, MCRA, or MRA) are a class of drugs that block the effects of aldosterone.

Therapy with MRA has a role in preventing these maladaptive effects in patients with CHF and left ventricular (LV) systolic dysfunction.7

MRAs block receptors that bind aldosterone and, with different degrees of affinity, other steroid hormones (e.g. corticosteroid and androgen) receptors. There are two types of MRAs namely Eplenorone and Spironolactone. Eplerenone is more specific for aldosterone blockade and, therefore, causes less gynecomastia.

What do Guidelines say?

Apart from the recommendations on indications, the guidelines also lay down various aspects for the use of MRA including dosage, how to use, what advice to give to patients as well as caution.

On the issue of Dosage the guidelines recommend starting with a low dose (Eplerenone/ Spironolactone: starting dose 25 mg once a day, target dose 50 mg once a day), and have continuous monitoring of blood chemistry at the given time intervals:

● 1 and 4 weeks after starting or increasing the dose

● 8 and 12 weeks

● 6, 9, and 12 months and 4-monthly thereafter

Also, dose up the titration after 48 weeks, states the guideline.

The guidelines call for doctors to ascertain a renal function and electrolyte level test before MRA therapy commencing. In case of potassium level rising above 5.5-6 mmol/L or creatinine rising to 221-310 lmol/L, immediately seek specialist advice.

Besides this, the guidelines also lay down what advice a doctor should give to the patient while prescribing them MRA. In particular, it states.

● Treatment is given to improve symptoms but may not be immediate and could be seen within a few months of starting the therapy

● Treatment is to prevent the worsening of HF leading to hospital admission and to increase survival.

● Avoid NSAIDs not prescribed by a physician/ over-the-counter and salt substitutes high in potassium.

The guidelines contraindicate the use of MRA in case of known allergic reactions. Also, guides the physician to seek cautions in certain conditions such as Significant hyperkalemia (K >5.0 mmol/L), significant renal dysfunction [creatinine > 221 lmol/L ( >2.5 mg/dL) or eGFR < 30 mL/min/1.73 m2 ].

Furthermore, the guideline states to look out for certain drug interactions, which includes (K supplements/K-sparing diuretics (e.g. amiloride and triamterene; beware combination preparations with furosemide), ACE-Is/ARBs/renin inhibitors, NSAIDs, Trimethoprim/trimethoprim-sulfamethoxazole, 'Low-salt' substitutes with a high K content, Strong CYP3A4 inhibitors, e.g. ketoconazole, itraconazole, nefazodone, telithromycin, clarithromycin, ritonavir, and nelfinavir (when eplerenone used).

References

1. Savarese, G., & Lund, L. H. (2017). Global Public Health Burden of Heart Failure. Cardiac failure review, 3(1), 7–11. https://doi.org/10.15420/cfr.2016:25:2

2. Huffman, Mark D, and DorairajPrabhakaran. "Heart failure: epidemiology and prevention in India." The National medical journal of India vol. 23,5 (2010): 283-8.

3. Nordgren L, Sorensen S. Symptoms experienced in the last six months of life in patients with end-stage heart failure. Eur J CardiovascNurs. 2003 Sep;2(3):213–217. [PubMed] [Google Scholar]

4. Zambroski CH, Moser DK, Bhat G, Ziegler C. Impact of symptom prevalence and symptom burden on quality of life in patients with heart failure. Eur J CardiovascNurs. 2005 Sep;4(3):198–206. [PubMed] [Google Scholar]

5. Alla F, Briancon S, Guillemin F, Juilliere Y, Mertes PM, Villemot JP, Zannad F. Self-rating of quality of life provides additional prognostic information in heart failure. Insights into the EPICAL study. Eur J Heart Fail. 2002 Jun;4(3):337–343. [PubMed] [Google Scholar]

6. Konstam V, Salem D, Pouleur H, Kostis J, Gorkin L, Shumaker S, Mottard I, Woods P, Konstam MA, Yusuf S. Baseline quality of life as a predictor of mortality and hospitalization in 5,025 patients with congestive heart failure. SOLVD Investigations. Studies of Left Ventricular Dysfunction Investigators. Am J Cardiol. 1996 Oct 15;78(8):890–895. [PubMed] [Google Scholar]

7. Enrico Vizzardi,* Valentina Regazzoni, Giorgio Caretta, Mara Gavazzoni, EdoardoSciatti, IvanoBonadei, EleftheriaTrichaki, Riccardo Raddino, and Marco Metra


heart failureHFrEFmineralocorticoid receptor antagonistMineralocorticoid receptor antagonistsmraesc heart failureEuropean Society of CardiologySpironolactoneEplenorone
Medical Dialogues Bureau
Medical Dialogues Bureau

    Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.

    Dr. Kamal Kant Kohli
    Dr. Kamal Kant Kohli

    Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

    Show Full Article
    Next Story

    Editorial

    National Consensus 2025 on Role of Bisoprolol Across CV Continuum in Women: Top 10 Takeaways

    National Consensus 2025 on Role of Bisoprolol Across CV Continuum in Women: Top 10 Takeaways

    Relevance of Pioglitazone in Indian T2DM Care Continuum

    Relevance of Pioglitazone in Indian T2DM Care Continuum

    Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

    Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

    First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

    First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

    Re-visiting the Role of Pneumococcal Vaccination in Patients with Cardiovascular Diseases

    Re-visiting the Role of Pneumococcal Vaccination in Patients with Cardiovascular Diseases

    View All

    Journal Club Today

    Study Reveals Why Your Immune System Works Better in Daylight

    Study Reveals Why Your Immune System Works Better in Daylight

    View All

    Health News Today

    Health Bulletin 28/May/2025

    Health Bulletin 28/May/2025

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok